强化阿托伐他汀对急性冠脉综合征C反应蛋白及血脂的影响

目的:观察不同剂量阿托伐他汀(10mg/d和40mg/d)早期干预对急性冠脉综合征(ACS)患者C反应蛋白(CRP)、血总胆固醇(TC)、低密度脂蛋白-胆固醇(LDL-C)水平的影响,以了解较大剂量阿托伐他汀对ACS患者免疫炎症抑制的影响及安全性。方法:72例ACS患者被随机分为两组,A组在常规治疗基础上予阿托伐他汀10mg/d,睡前口服;B组在常规治疗基础上予阿托伐他汀40mg/d,睡前口服,均在入院48h内开始用药,治疗4周,分别予用治疗前、后监测血清CRP、血脂(TC、LDL-C)浓度,同时观察用药安全性。结果:治疗后两组患者血清CRP、血脂均有不同程度的下降(P0.05～0.01),与A组相比较,B组CRP(16.45±6.45)mg/L:(11.48±6.83)mg/L]、TC(5.38±0.64)mmol/L:(4.92±0.50)mmol/L]、LDL-C(2.53±0.46)mmol/L:(1.95±0.39)mmol/L]下降更明显(P均0.05)。两组均无严重不良事件。结论:较大剂量阿托伐他汀早期干预治疗可显著降低急性冠脉综合征患者血清C反应蛋白浓度及血脂水平,并具有良好的安全性。。

Influence of augmentation atorvastatin treatment early on the serum lipid and C reactive protein in patients with acute coronary syndrome

Objective： To investigate the influence of augmentation atorvastatin treatment early on the serum lipid and C reactive protein （CRP） in patients with acute coronary syndrome and its safely. Methods： Total of 72 patients were divided into two groups randomly： atorvastatin control group （group A, atorvastatin was 10 mg/d based routine therapy） and augmentation atorvastatin group （group B, atorvastatin was 40 mg/d based routine therapy）. Therapeutic time was 4 weeks. Serum total cholesterol （TC）, low density lipoprotein-cholesterol （LDL-C） and CRP contents were measured before and after therapy. Results： After therapy, the serum lipid and CRP levels all significantly decreased in two groups （P〈0. 054〈0.01）, but compared with group A, the CRP （16.45±6.45） mg/L vs. （11.48 ±6.83） mg/L], TC （5.38±0.64） mmol/L vs. （4.92±0.50） mmol/L], LDL-C （2.53±0.46） mmol/L vs. （1. 95±0.39） mmol/L], were more decreased （P〈0.05 all） in group B. There were no serious harmful event in two groups. Conclusion： Augmentation atorvastatin treatment may more decrease CRP and serum lipid levels and is safe.